



Published in final edited form as:

*Pediatr Res.* 2017 August ; 82(2): 272–277. doi:10.1038/pr.2017.58.

## Pediatric Cushing Disease: Disparities in Disease Severity and Outcomes in the Hispanic and African American Populations

Alexandra Gkourogiani<sup>1</sup>, Ninet Sinaii<sup>2</sup>, Sharon H. Jackson<sup>3</sup>, Alexander S. Karageorgiadis<sup>1,4</sup>, Charalampos Lyssikatos<sup>1</sup>, Elena Belyavskaya<sup>1</sup>, Margaret F. Keil<sup>1</sup>, Mihail Zilbermint<sup>1,5,6</sup>, Prashant Chittiboina<sup>7</sup>, Constantine A. Stratakis<sup>1</sup>, and Maya B. Lodish<sup>1,\*</sup>

<sup>1</sup>Section on Endocrinology and Genetics, Developmental Endocrinology Branch, and Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland <sup>2</sup>Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, Bethesda, Maryland <sup>3</sup>National Institute on Minority and Health Disparities, NIH, Bethesda, Maryland <sup>4</sup>Department of Pediatrics, Georgetown University Hospital, Washington, DC <sup>5</sup>Johns Hopkins University School of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Baltimore, Maryland <sup>6</sup>Suburban Hospital, Bethesda, Maryland <sup>7</sup>Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland

### Abstract

**Background**—Little is known about the contribution of racial and socioeconomic disparities to severity and outcomes for children with Cushing disease (CD).

**Methods**—129 children with CD, 45 Hispanic/Latino or African American (HI/AA) and 84 non-Hispanic White (non-HW), are included. A 10-point index for rating severity (CD-severity) incorporated degree of hypercortisolemia, glucose tolerance, hypertension, anthropomorphic measurements, disease duration, and tumor characteristics. Race, ethnicity, age, gender, local obesity prevalence, estimated median income, and access to care were assessed in regression analyses of CD-severity.

**Results**—The mean CD-severity for the HI/AA group was worse than the non-HW group ( $4.9 \pm 2.0$  vs  $4.1 \pm 1.9$ ,  $p = 0.023$ ); driving factors included higher cortisol levels and larger tumor size. Multiple regression models confirmed that race ( $p=0.027$ ) and older age ( $p=0.014$ ) were the most important predictors of worse CD-severity. When followed up a median of 2.3 years after surgery, the relative risk of persistent CD combined with recurrence was 2.8 times higher in HI/AA compared to non-HW (95% CI: 1.2–6.5).

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Correspondence: Maya Lodish (lodishma@mail.nih.gov) National Institute of Child Health and Human Development, Building 10-CRC, Room 1-3330 10 Center Drive, MSC 1103 Bethesda, MD 20892 Phone: 301-451-7175.

Disclosure Statement: The authors have no disclosures to report

**Conclusions**—Our data show that the driving forces for the discrepancy in severity of CD are older age and race/ethnicity. Importantly, risk of persistent and recurrent CD was higher in minority children.

---

## Introduction

An estimated 1 to 1.5 per million children are affected a year by Cushing syndrome; of those 75–80% are caused by an adrenocorticotrophic hormone (ACTH) secreting pituitary tumor (Cushing disease, CD) (1). Prolonged exposure to excess glucocorticoids leads to obesity, growth deceleration, striae, muscle weakness, and hypertension, impaired glucose intolerance, osteopenia/osteoporosis, and alterations in cognitive function and mood (2). These tumors are typically benign and early identification and surgical resection may lead to long-term remission and cure (3). Importantly, improved outcomes in children with CD are associated with younger age at surgery, smaller adenomas and lack of dural invasion (3).

Racial, ethnic, and socioeconomic disparities have been investigated in a number of diseases associated with tumors; significant differences in disease incidence, prevalence, and mortality have been identified (4–6). Even as treatment and detection of tumors have improved, African-Americans continue to experience lower survival rates than whites for all cancers (7). For the most common childhood cancer, acute lymphoblastic leukemia, Black, and Hispanic children have worse survival than white children; in addition, SES is associated with poor survival in childhood leukemia (8,9). 5-year survival rates among Hispanics (HI) (74%) and African American (AA) (75%) children remains poorer than that among non-Hispanic Whites (non-HW) (85%) for CNS malignancies as well as for many other tumors (5,10). While disproportionate morbidity and mortality have been shown for more common cancers, no prior studies have examined differences in severity of presentation for children with CD. In addition to looking at individual clinical parameters and comparing them between racial groups, we also introduced a combined pediatric CD severity score (CD-severity) as a tool for research purposes. As has been done in other disease states when severity scores are formulated, we looked at the comorbidities associated with CD. Each of the individual factors used in the scoring system has independently been associated with an increased risk of a poor outcome for patients (degree of hypercortisolemia, impaired glucose tolerance, hypertension, height impairment BMI, delay in diagnosis, and larger tumor (3,11,12). Our severity score aims to quantify the magnitude of glucocorticoid exposure in order to characterize the severity of illness. In addition, inhibition of linear growth by exogenous steroids has been shown to be dose-dependent, a unique factor in children vs. adults with CD. In adults with CD, hypertension and diabetes are known to be the main determinants of cardiovascular events and mortality; we wanted to capture these signs in children as important determinants of overall disease severity (13–16). In the current study, we examined data to assess CD-severity at presentation and risk of persistent disease and/or relapse.

## Methods

### Subjects

Patients with CD  $\geq$  18 years at the time of transsphenoidal surgery (TSS) were consecutively treated at the National Institutes of Health Clinical Center (NIH CC) from January 1, 1997 through January 1, 2015. Informed consent and assent was obtained in all patients. The Institutional Review Boards of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) NIH, approved the research protocol (Clinical Trial Registration number: NCT00001595)

### Study Design

Patients were admitted for pre-operative testing within 1 month of their surgical date to confirm CD following a standardized protocol. A venous sampling catheter was placed at least 2 hours before the test; cortisol and ACTH levels were drawn at 23:30 and 24:00, these values were averaged to become the “Average” late night cortisol value. Preoperative evaluation included: 1) 24-hour urinary free cortisol (24-h UFCs), 2) average late night (23:30 h, 24:00 h) and morning (07:30 h, 08:00 h) serum cortisol levels, as well as 3) average morning (7:30 h, 8:00 h) plasma ACTH levels. The initial visit data included the age at surgery, gender, race/ethnicity (by self-report), number of TSS, years of hypercortisolism (as determined by review of growth chart and age of crossing percentiles for height and weight, as well as self-report of onset of physical symptoms of CD) height, height z-score, weight, body mass index (BMI), BMI z-score. BMI (kilogram per meter squared) and BMI – for –age z-scores were calculated from the Centers for Disease Control and Prevention (CDC) growth charts (17). Surgical outcome, length of follow up, as well as rates of recurrent CD were collected. A 10-point index for rating severity in pediatric CD (CD-severity) (Table 1) was devised based on review of the most clinically relevant manifestations in children, the co-morbidities associated with CD, and the independent association of each factor with risk of a poor clinical outcome. Seven clinical features were selected on the basis of their frequency and importance. Degree of hypercortisolemia, impaired glucose tolerance, and hypertension were graded on an ordinal 3-point scale (0–2) with pre-defined cut-offs based on severity. Height and BMI z-scores, duration of disease, tumor size, and presence of tumor invasion were graded on an ordinal 2-point scale (0–1). Total severity scores ranged from 0–10. Estimated income data was obtained from US Census and World Bank databases, using zip codes of residence for US census data (18,19). Prevalence of obesity in children by state was extrapolated from the Data Resource Center for Child and Adolescent Health, a project of the Child and Adolescent Health Measurement Initiative (CAHMI-2011) where obese children with BMI z-score  $\geq$  95% ile are reported by state (Table 2) (20). Access to pediatric endocrinologists by state was based on the relative distribution of American Board of Pediatrics certified Pediatric Endocrinology Diplomates by state as of 12/31/2012 (Table 2) (21). Status of country in terms of whether or not it is developed was based on the International Monetary Fund’s World Economic Outlook Report, April 2015 (22).

## Data Analysis

Results were described as frequencies and percentages, or means and standard deviations, unless otherwise indicated. Groups were defined based on self-reported racial and ethnic descriptions, and were categorized as Hispanic/Latino or African American (HI/AA) if they indicated Hispanic or Latino ethnicity or indicated Black/African American race regardless of ethnicity. The non-Hispanic white (non-HW) category consisted of those that indicated not Hispanic or Latino for ethnicity and white for race. Those not meeting these definitions were excluded. Data were assessed for their distributions and log-transformed as necessary. Continuous data were compared using the two-sample t-test or Wilcoxon rank-sum test, as applicable; categorical data were compared by the chi-square or Fisher's exact test, and Kruskal-Wallis test was used for singly ordered categories. Simple and multiple regression analyses were carried out to assess the relation between explanatory variables (race/ethnicity, age, gender, prevalence of obesity in children by state, estimated median income per zip-code, access to pediatric endocrinologists, and whether an individual resided in a developing country) and disease severity outcome as scored by the index described above. The Kaplan-Meier method was used to compute the survivor function for time to recurrence that were compared between the two groups using the log-rank test. Data were considered statistically significant if the resulting p-value was less than 0.05, or the relative risk (RR) 95% Confidence Interval (CI) excluded 1.0. Corrected p-values are reported for post-hoc comparisons which utilized the Bonferroni method. Analyses were done using SAS v9.4 (SAS Institute, Inc., Cary, NC).

## Results

From an initial population of 139 pediatric CD patients admitted to the National Institutes of Health Clinical Center (NIH CC) between the years 1997–2015, data were collected retrospectively from records of children diagnosed with CD at age 18 years (64 females, 65 males, median age 13.4 years). The year 1997 coincided with the initiation of our protocol entitled “A Clinical and Genetic Investigation of Pituitary Tumors and Related Hypothalamic Disorders,” in which these patients were enrolled, as well as they year that standardization of racial and ethnic designations were revised by the Office of Management and Budget (23). Patient racial/ethnic groups were distributed as 34.9% (n=45) HI/AA and 65.1% (n=84) non-HW. Asian patients (n=6) and those with unknown race/ethnicity (n=4) were excluded from the study; thus, a total of 129 patients were included in the analysis. The complete datasets, stratified by race/ethnicity showing both HI, AA, and non-HW data individually as well as HI and AA grouped together, are shown in Tables 2 and 3.

Median income was higher in the non-HW group and fewer from the non-HW group were from developing countries (both  $p < 0.001$ ; Table 2) than the HI/AA group. The developing countries where our patients reside, followed by the number of patients from each country: Peru (5), Chile (4) Brazil (3), and one child each from Colombia, Ecuador, Guatemala, Venezuela, Uruguay, and Argentina.

Midnight cortisol was higher in the HI/AA group ( $23.3 \pm 22.0 \mu\text{g/dL}$  vs  $16.2 \pm 8.5 \mu\text{g/dL}$ ,  $p=0.040$ ), and height SDS score was more severely affected ( $-1.6 \pm 1.2$  vs  $-1.1 \pm 1.1$ ,

$p=0.022$ ), than non-HW. Tumor size was also larger in HI/AA ( $6.3 \pm 7.1$  mm vs  $3.2 \pm 3.3$  mm,  $p=0.007$ ).

The mean CD-severity score for HI/AA was worse than for the non-HW group ( $4.9 \pm 2.0$  vs  $4.1 \pm 1.9$ ,  $p=0.023$ ). Simple regression analysis of disease severity revealed that age was an independent explanatory variable of disease severity as measured by CD-severity ( $r_p=0.23$ ,  $p=0.008$ ), while gender, number of pediatric endocrinologists per capita, median income, prevalence of obesity in the patient's state of residence, and whether or not an individual resided in a developing country were not independent driving factors. Considering these effects together in multiple regression models confirmed that race ( $p=0.027$ ) and older age ( $p=0.014$ ) were the most important predictors of worse CD-severity.

### Follow up

Of the 129 children in this study, 124 achieved remission after surgery. Of the 5 patients who did not achieve remission after surgery, two then underwent radiation therapy and three were managed with ketoconazole. Long-term follow up was available in 112 patients (87%) with mean postoperative follow up  $45.5 \pm 39.9$  months, median follow up 27.9 months (IQR=13.2–68.7 months), range 1.4–158.7 months. Interestingly, follow up was available in more non-HW individuals, 78/84 (93%) as compared to 34/45 (76%) of HI/AA individuals ( $p=0.012$ ), and mean CD-severity was significantly worse in those individuals without long-term follow up ( $5.4 \pm 1.7$  vs  $4.2 \pm 2.0$ ,  $p=0.017$ ). Thirteen of the 108 patients with long term follow up (excluding those who had persistent disease) developed recurrent CD over the course of the study, with a mean time to recurrence  $49.2 \pm 28.2$  months, range 1.9 to 111.3 months. Of these individuals, one underwent bilateral adrenalectomy, three were treated with pituitary radiation therapy, two underwent repeat pituitary surgery in addition to pituitary radiation therapy, six underwent repeat TSS alone, and one individual is awaiting repeat surgery. Two individuals are currently deceased, one secondary to suicide and another from pulmonary embolism. Overall, 13 patients had recurrence of disease after surgery and 5 had persistent disease after surgery. As expected, CD-severity was worse among those individuals with recurrent disease ( $5.1 \pm 1.7$  vs  $4.1 \pm 1.9$ ,  $p=0.041$ ). Among those individuals with long term follow up or known persistence of disease after surgery, a higher proportion of individuals in the HI/AA group had lack of initial cure or recurrence (10 out of 35 AA/HI, 28.6%) when compared to non-HW (8 out of 78, 10.3%,  $p=0.024$ ). The relative risk of persistent CD combined with recurrence was 2.8 times higher in HI/AA as compared to non-HW (95% CI: 1.2–6.5). When disease free survival is compared (time in remission), the median for HI/AA 26.8 (95% CI: 13.2–50.3) months vs. non-HW 34.8 (95% CI: 19.7–60.1) months; log-rank  $p=0.028$  (Figure 1).

### Discussion

Our findings show disproportionately higher severity of CD in the HI/AA patients both preoperatively and postoperatively. SES was also lower in the HI/AA individuals. SES status contributes to health disparities as poverty, lack of health insurance, and poor access to care cause the medically underserved to bear a greater burden of disease than the general population. In the United States, both African American and Hispanic/Latino minority

groups have lower SES, decreased access to healthcare, and worse outcomes across a number of health indicators compared to whites (24). For all cancer sites combined, residents of poorer countries have higher death rates from cancer compared to more affluent countries (25). Later stage at diagnosis of cancer has been associated with lower SES (6). It follows that the HI/AA children in our study had a higher proportion diagnosis at an advanced stage; children of low-income families may have limited access to specialized care and cancer diagnosis, including CD, may be delayed (26,27).

One potential cause for worse CD-severity scores in the HI/AA group may be the higher prevalence of obesity in minority children, which may lead practitioners to overlook one of the presenting symptoms of CD. Obesity prevalence for non-Hispanic white youth and young adults is 14.1%, while the prevalence for Hispanic/Latinos and African Americans is 22.4% and 20.2%, respectively (28). In addition, delayed referral for surgical intervention or participation in a clinical trial for a rare disease may be contributing factors for the higher severity in the HI/AA children with CD. TSS is the treatment of choice with optimal outcomes when performed at tertiary referral centers (1). Racial and socioeconomic disparities have been found specifically for children in terms of access to high-volume neurooncological care (29). In addition, minorities with cancer are underrepresented in pediatric oncology research protocols (30).

Social factors including race/ethnicity, educational level, language/culture barriers, income, poverty, unemployment, and lack of health insurance all contribute to health outcomes, in addition to one's genetic background (10,25). Progress in pediatric cancer survival rates is highly attributable to early detection and advances in therapeutic protocols, and patients' participation in clinical trials (7). The association of younger age, smaller tumor size, and absence of cavernous sinus invasion (experienced surgeon and center of referral) with lasting biochemical remission suggests that earlier diagnosis when the tumor is small and non-invasive will enhance long term outcome; late pituitary CD diagnoses are associated with more comorbidities and higher recurrence and mortality rates (3). Awareness of the signs and symptoms of CD needs to be increased among care providers. We suggest the American Cancer Society (ACS) and ACS Cancer Action Network together should influence public policies and promote patient's navigators and medical homes in order to reduce health disparities (31–33).

Our study is the first to introduce a combined severity score for childhood CD, which we observed to be associated with outcome; that is, the higher the severity score, the higher the likelihood of recurrence and failure to cure. One limitation of our study associated with the use of a novel severity score for pediatric CD is that it has yet to be validated in a larger cohort. Given the rarity of childhood CD, we will work towards collaborating with other institutions to validate the performance of the severity scoring system. Another limitation of our study is the use of residential zip codes as a proxy for income that may not account for within-area variation. In addition, patient health insurance status is not collected at the NIH Clinical Center as patients are participating in a research study.

HI/AA children had comparatively more severe disease presentation of CD compared with non-HW, and a nearly three-fold higher risk of persistent CD or recurrent disease after



surgery. Our data show that the driving forces for the discrepancy in disease severity are older age at time of treatment and race. Delayed diagnosis and treatment and lack of access to care for these underserved children may contribute to presentation at a later age and increased morbidity. We speculate that delayed diagnosis and treatment, barriers to access to medical care, and poorer quality health care for these underserved patients may contribute to presentation at a later age and increased morbidity. Additional research is needed to identify potential modifiable factors that may improve care for these patients.

## Acknowledgments

### Statement of Financial Support


This research was supported in part by the Intramural Research Program of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, National Institutes of Health (NIH). National Institutes of Health. Clinical Trial Registration No.: NCT00001595.

## References

1. Stratakis CA. Cushing syndrome in pediatrics. *Endocrinol Metab Clin North Am*. 2012; 41:793–803. [PubMed: 23099271]
2. Lodish M. Cushing's syndrome in childhood: update on genetics, treatment, and outcomes. *Curr Opin Endocrinol Diabetes Obes*. 2015; 22:48–54. [PubMed: 25517021]
3. Lonser RR, Wind JJ, Nieman LK, Weil RJ, DeVroom HL, Oldfield EH. Outcome of surgical treatment of 200 children with Cushing's disease. *J Clin Endocrinol Metab*. 2013; 98:892–901. [PubMed: 23372173]
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin*. 2011; 61:212–36. [PubMed: 21685461]
5. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975–1999. *Cancer*. 2008; 113:2575–96. [PubMed: 18837040]
6. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. *Cancer Causes Control*. 2009; 20:417–35. [PubMed: 19002764]
7. Zeng C, Wen W, Morgans AK, Pao W, Shu XO, Zheng W. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010. *JAMA Oncol*. 2015; 1:88–96. [PubMed: 26182310]
8. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. *JAMA*. 2003; 290:2008–14. [PubMed: 14559954]
9. Petridou ET, Sergentanis TN, Perlepe C, et al. Socioeconomic disparities in survival from childhood leukemia in the United States and globally: a meta-analysis. *Ann Oncol*. 2015; 26:589–97. [PubMed: 25527416]
10. Bhatia S. Disparities in cancer outcomes: lessons learned from children with cancer. *Pediatr Blood Cancer*. 2011; 56:994–1002. [PubMed: 21328525]
11. Lodish MB, Sinaii N, Patronas N, et al. Blood pressure in pediatric patients with Cushing syndrome. *J Clin Endocrinol Metab*. 2009; 94:2002–8. [PubMed: 19293264]
12. Aicardi G, Benso L, Vignolo M, et al. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation. *Br J Rheumatol*. 1993; 32(Suppl 2):39–43.
13. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. *Clin Endocrinol (Oxf)*. 1994; 40:479–84. [PubMed: 8187313]
14. Bolland MJ, Holdaway IM, Berkeley JE, et al. Mortality and morbidity in Cushing's syndrome in New Zealand. *Clin Endocrinol (Oxf)*. 2011; 75:436–42. [PubMed: 21609352]

15. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. *J Clin Endocrinol Metab.* 2011; 96:632–42. [PubMed: 21193542]
16. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients. *J Clin Endocrinol Metab.* 2013; 98:1022–30. [PubMed: 23393167]
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. *Adv Data.* 2000:1–27.
18. The World Bank. Gross national income per capita ranking table based on the World Bank Atlas method and purchasing power parity. 2015. (<http://data.worldbank.org/data-catalog/GNI-per-capita-Atlas-and-PPP-table>)
19. The United States Census. 2012 Economic Census Data. (<https://www.census.gov/econ/geo-zip>.)
20. Data Resource Center for Child and Adolescent Health. National Survey of Children's Health (NSCH) Child and Adolescent Health Measurement Initiative. 2011. (<http://www.childhealthdata.org>.)
21. American Board of Pediatrics. Pediatric workforce data, Number of ABP Pediatric Endocrinology Diplomates by State. 2015. (<https://www.abp.org/content/workforce-data>.)
22. International Monetary Fund Fund. World Economic Outlook Database. 2015. (<http://www.imf.org/external/pubs/ft/weo/2015/01/weodata/index.aspx>)
23. OMB (Office of Management and Budget) Revisions to the standards for the classification of federal data on race and ethnicity. *Fed Regist.* 1997; 62:58781–58790.
24. Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. *Lancet Oncol.* 2008; 9:222–31. [PubMed: 18282806]
25. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. *CA Cancer J Clin.* 2004; 54:78–93. [PubMed: 15061598]
26. Mukherjee D, Zaidi HA, Kosztowski T, et al. Disparities in access to neuro-oncologic care in the United States. *Arch Surg.* 2010; 145:247–53. [PubMed: 20231625]
27. Mukherjee D, Zaidi HA, Kosztowski T, et al. Predictors of access to pituitary tumor resection in the United States, 1988–2005. *Eur J Endocrinol.* 2009; 161:259–65. [PubMed: 19447900]
28. Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988–1994 Through 2013–2014. *JAMA.* 2016; 315:2292–9. [PubMed: 27272581]
29. Mukherjee D, Kosztowski T, Zaidi HA, et al. Disparities in access to pediatric neurooncological surgery in the United States. *Pediatrics.* 2009; 124:e688–96. [PubMed: 19786429]
30. Aristizabal P, Singer J, Cooper R, et al. Participation in pediatric oncology research protocols: Racial/ethnic, language and age-based disparities. *Pediatr Blood Cancer.* 2015; 62:1337–44. [PubMed: 25755225]
31. Moy B, Polite BN, Halpern MT, et al. American Society of Clinical Oncology policy statement: opportunities in the patient protection and affordable care act to reduce cancer care disparities. *J Clin Oncol.* 2011; 29:3816–24. [PubMed: 21810680]
32. Srinivasan S, Williams SD. Transitioning from health disparities to a health equity research agenda: the time is now. *Public Health Rep.* 2014; 129(Suppl 2):71–6. [PubMed: 24385668]
33. Strickland BB, Jones JR, Ghandour RM, Kogan MD, Newacheck PW. The medical home: health care access and impact for children and youth in the United States. *Pediatrics.* 2011; 127:604–11. [PubMed: 21402643]





**Figure 1.**

The Kaplan-Meier curves for disease free survival in HI/AA and non-HW study groups (time in remission) HI/AA median=26.8 (95% CI: 13.2–50.3) months vs. non-HW median=34.8 (95% CI: 19.7–60.1) months; log-rank  $p=0.028$ ].

**Table 1**

## Cushing Disease Severity Score

Severity Score Component	To capture	Cut - off	Component Score
S1	Degree of hypercortisolemia	MSC &/or 24h-UFC < 50% ile	0
		MSC &/or 24h-UFC 50% ile – < 75% ile	1
		MSC &/or 24h-UFC 75% ile	2
S2	IGT	FPG < 100 mg/dL	0
		FPG 100 mg/dL	1
		FPG 126 mg/dL &/or DM-Dx	2
S3	Hypertension	SBP & DBP z-score both < 2	0
		SBP or DBP z-score 2	1
		HTN-Tx	2
S4	Height z-score	Height z-score > -0.5	0
		Height z-score -0.5	1
S5	BMI z-score	BMI z-score < 2	0
		BMI z-score 2	1
S6	t (to diagnosis)	< 3 years	0
		3 years	1
S7	Tumor characteristics (size & invasion)	Adenoma size < 5 mm	0
		Adenoma size 5 mm &/or CS invasion	1

**Abbreviations:** MSC= Midnight Serum Cortisol, 24h-UFC= 24 hour Urine Free Cortisol, IGT= Impaired Glucose Tolerance, FPG= Fasting Plasma Glucose, DM= Diabetes Mellitus, DM-Dx= Diabetes Mellitus Diagnosis, DM-Tx= Diabetes Mellitus treatment with insulin or metformin at diagnosis, BP z-score= Blood Pressure z-score, SBP= Systolic Blood Pressure, DBP= Diastolic Blood Pressure, HTN-Tx= On medication for hypertension at diagnosis, BMI= Body Mass Index, t (to diagnosis)= Duration from first symptoms to diagnosis, CS= cavernous sinus.

**SI conversion factors:** To convert fasting plasma glucose to mmol/L, multiply values by 0.0555.

**CD Severity Score** = sum of S1–S7

**Table 2**  
Demographic characteristics of 129 children with Cushing Disease, stratified by race/ethnicity.

Variable	Hispanic (n= 36)	African American (n=9)	Non-Hispanic White (n= 84)	P-value <sup>1</sup>	Hispanic or African American (n= 45)	P-value <sup>2</sup>
Age (years)	13.4 ± 3.5	13.8 ± 2.2	12.9 ± 3.2	0.61	13.5 ± 3.3	0.34
BMI z-score	1.9 ± 0.8	2.4 ± 0.4	2.1 ± 0.7	0.25	2.0 ± 0.8	0.64
Height z-score	-1.4 ± 1.2	-2.0 ± 1.1	-1.1 ± 1.1	<b>0.030*</b>	-1.6 ± 1.2	<b>0.022*</b>
Gender (F)	21 (58%)	3 (33%)	40 (48%)	0.35	24 (53%)	0.58
Median income	\$29,406 ± \$36,034	\$66,128 ± \$34,935	\$59,231 ± \$31,314	<b>&lt;0.001*<sup>c</sup></b>	\$37,466 ± \$38,564	<b>&lt;0.001**</b>
<b>Prevalence of obesity in resident state<sup>d</sup></b>				0.63		0.76
20.1%	0	1 (11.1%)	9 (12.3%)		1 (4.6%)	
15.1%–20%	3 (23.1%)	4 (44.4%)	22 (30.1%)		7 (31.8%)	
10.1%–15%	10 (76.9%)	4 (44.4%)	37 (50.7%)		14 (63.6%)	
5.1%–10%	0	0	5 (6.9%)		0	
0%–5%	0	0	0		0	
<b>Pediatric endocrinologist per-capita score<sup>b</sup></b>	3.9 ± 1.0	3.6 ± 1.5	3.3 ± 1.2	0.29	3.7 ± 1.2	0.097
<b>Individuals from a developing country</b>	18 (50%)	0	3 (3.6%)	<b>&lt;0.001*<sup>d</sup></b>	18 (40.0%)	<b>&lt;0.001**</b>

Data are mean ± standard deviation or frequency (percent). Sums may not add up to total numbers due to missing or not applicable (ie, state information for non-US patients) data.

P-Values: 1: Comparing all three groups; 2: Comparing combined Hispanic or African American to Non-Hispanic White.

<sup>a</sup>Percentage of children with BMI z-score at 95% tile for each patient's resident US state, scores of 1–5 correspond as follows: 1 (20.1%), 2 (15.1%–20%), 3 (10.1%–15%), 4 (5.1%–10%), 5 (0%–5%).

<sup>b</sup>Pediatric endocrinologists per-capita score for each patient's resident US state: 0 (no certified specialists), 1 (1:150,000+), 2 (1:100,000–149,000), 3 (1:75,000–99,999), 4 (1:50,000–74,999); 5 (1:49,999).

<sup>c</sup>post-hoc corrected p=0.011 for Hispanic vs African American and p<0.001 for Hispanic vs Non-Hispanic White.

<sup>d</sup>post-hoc corrected p=0.013 for Hispanic vs African American and p<0.001 for Hispanic vs Non-Hispanic White.

**Abbreviations:** BMI= Body Mass Index; US = United States, F= female.

Table 3

Patient characteristics of 129 children with Cushing Disease as they relate to severity of presentation, stratified by race/ethnicity.

Variable	Hispanic (n=36)	African American (n=9)	Non-Hispanic White (n=84)	Hispanic or African American (n= 45)	P-value <sup>1</sup>	P-value <sup>2</sup>
MSC (µg/dL)	25.1 ± 23.9	16.1 ± 10.3	16.2 ± 8.5	23.3 ± 22.0	<b>0.038</b> <sup>a,d</sup>	<b>0.040</b> <sup>*</sup>
24h-UFC (µg/24h)	905.3 ± 2,561.1	453.5 ± 612.2	263.4 ± 237.7	815.0 ± 2,306.3	0.21	0.13
Adenoma size (mm)	6.0 ± 6.7	7.4 ± 8.9	3.2 ± 3.3	6.3 ± 7.1	<b>0.025</b> <sup>a,b</sup>	<b>0.007</b> <sup>**</sup>
CS Invasion	4 (11.1%)	1 (11.1%)	3 (3.6%)	5 (11.1%)	0.22	0.13
DM-Tx	6 (16.7%)	1 (11.1%)	4 (4.8%)	7 (15.6%)	0.087	<b>0.049</b> <sup>*</sup>
HTN-Tx	9 (25.0%)	3 (33.3%)	12 (14.3%)	12 (26.7%)	0.17	0.10
t (to diagnosis) (years)	2.8 ± 2.1	4.2 ± 2.3	2.5 ± 1.5	3.1 ± 2.2	0.089	0.37
CD-severity score (0–10)	4.6 ± 1.8	6.0 ± 2.5	4.1 ± 1.9	4.9 ± 2.0	<b>0.012</b> <sup>a,c</sup>	<b>0.023</b> <sup>*</sup>

Data are mean ± standard deviation or frequency (percent).

P-values: 1: Comparing all three groups; 2: Comparing combined Hispanic or African American to Non-Hispanic White.

<sup>a</sup> = post-hoc corrected p=0.040 for Hispanic vs Non-Hispanic White,

<sup>b</sup> = post-hoc corrected p=0.041 for Hispanic vs Non-Hispanic White,

<sup>c</sup> = post-hoc corrected p=0.014 for African American vs Non-Hispanic White.

**Abbreviations:** MSC= Midnight Serum Cortisol, 24h-UFC= 24 hour Urine Free Cortisol, CS Invasion= Invasion of cavernous sinus, DM-Tx= Diabetes Mellitus treatment with insulin or metformin at diagnosis, HTN-Tx= On treatment for hypertension at diagnosis, t (to diagnosis)= Duration from symptoms to diagnosis, CD= Cushing Disease, **SI conversion factors:** To convert midnight cortisol to nmol/L, multiply values by 27,588.

To convert 24h-Urinary free cortisol (µg/24h) to nmol/24h multiply values by 2.76 (molecular weight= 362.5).